 This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer will be treated with RAD001 to evaluate the target effects of this compounds on relevant molecular pathways and on the 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose FDG uptake of the tumor by a positron emission tomography PET scan at baseline and immediately prior to surgery. The safety profile of RAD001 will also be evaluated. 